TARS2

Across TCGA pan-cancer cohorts, TARS2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TARS2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TARS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TARS2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

HNSC, BRCA, and SARC are the cancer types where TARS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.198	0.768	.001	27	view →
BRCA	OS	Median	III,IV	0.027	0.907	<.001	16	view →
SARC	DFS	Median	All	0.163	0.613	.017	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	0.071	0.212	.007	5	view →
BLCA	DFS	Median	IV	1.000	0.196	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TARS2–HNSC (OS)

Open the HNSC breakdown →